Itaconix (ITX) H1 2025 earnings summary

Executive summary

• Achieved record H1 2025 revenues of $4.8M, up 73% year-over-year and 30% sequentially, with gross profit of $1.7M, and near-neutral adjusted EBITDA loss of $(0.2)M, reflecting significant operational improvement.

• Major commercial progress with expansion in North America and Europe, leveraging proprietary itaconic acid-based polymers and a "land & expand" strategy to grow the customer base.

• Advanced growth initiatives including SPARX program (formulated solutions) and BIO*Asterix (specialty monomers), with new product launches and expanded partnerships such as Croda.

• Maintained strong working capital of $6.6M and cash/investments of $5.7M at period end, supporting future growth.

• Loss after tax improved to $(0.4)M from $(1.0)M in H1 2024, with basic and diluted loss per share improving to $(0.03).

Financial highlights

• Revenue grew 73% year-over-year to $4.8M, with gross profit up 55% to $1.7M and gross margin stable at 35%.

• Adjusted EBITDA loss improved to $(0.2)M from $(1.0)M in H1 2024.

• Performance Ingredients revenue rose 51% to $3.3M (45% margin); SPARX solutions up 156% to $1.5M (13% margin).

• North America accounted for 68% of sales ($3.3M), Europe and global 32% ($1.5M), with EU revenue up 161% year-over-year.

• Working capital at $6.6M; cash and investments at $5.7M at June 30, 2025.

Outlook and guidance

• Confident in meeting 2025 and 2026 expectations, with profitability expected after one more major revenue step.

• Focus on expanding scale inhibitors in detergents, growing SPARX solutions, and developing BIO*Asterix monomers.

• Plans to launch 10 new SPARX products in 2025 and another 8 in 2026.

• Well positioned with $5.7M in cash and a robust pipeline of opportunities.

• Exploring global expansion, with regulatory approvals in Asia-Pacific and ongoing projects with major global brands.